159 related articles for article (PubMed ID: 8613907)
1. Haloperidol and apomorphine differentially affect neuropeptidase activity.
Waters SM; Konkoy CS; Davis TP
J Pharmacol Exp Ther; 1996 Apr; 277(1):113-20. PubMed ID: 8613907
[TBL] [Abstract][Full Text] [Related]
2. Effect of dopaminergic drugs on processing and degradative neuropeptidase mRNA in rat frontal cortex and caudate-putamen.
Waters SM; Rounseville MP; Davis TP
Brain Res; 1997 Apr; 754(1-2):28-34. PubMed ID: 9134956
[TBL] [Abstract][Full Text] [Related]
3. Neuropeptide metabolism on intact, regional brain slices: effect of dopaminergic agents on substance P, cholecystokinin and Met-enkephalin degradation.
Waters SM; Konkoy CS; Davis TP
J Pharmacol Exp Ther; 1995 Aug; 274(2):783-9. PubMed ID: 7543572
[TBL] [Abstract][Full Text] [Related]
4. Acute administration of neuroleptics decreases neurotensin metabolism on intact, regional rat brain slices.
Konkoy CS; Waters SM; Davis TP
J Pharmacol Exp Ther; 1994 May; 269(2):555-63. PubMed ID: 7910209
[TBL] [Abstract][Full Text] [Related]
5. Chronic treatment with neuroleptics alters neutral endopeptidase 24.11 activity in rat brain regions.
Konkoy CS; Oakes MG; Davis TP
Peptides; 1993; 14(5):1017-20. PubMed ID: 7904340
[TBL] [Abstract][Full Text] [Related]
6. Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment.
Zhang Y; Xu H; He J; Yan B; Jiang W; Li X; Li XM
Neurosci Lett; 2007 Jun; 420(1):66-71. PubMed ID: 17466452
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic regulation of orexin neurons.
Bubser M; Fadel JR; Jackson LL; Meador-Woodruff JH; Jing D; Deutch AY
Eur J Neurosci; 2005 Jun; 21(11):2993-3001. PubMed ID: 15978010
[TBL] [Abstract][Full Text] [Related]
8. Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning.
Feifel D; Priebe K; Johnstone-Miller E; Morgan CJ
Psychopharmacology (Berl); 2002 Jul; 162(2):138-46. PubMed ID: 12110991
[TBL] [Abstract][Full Text] [Related]
9. Effects of CI-943, a potential antipsychotic drug, and haloperidol on regional brain neurotensin concentrations.
Levant B; Bissette G; Davis MD; Heffner TG; Nemeroff CB
Synapse; 1991 Nov; 9(3):225-30. PubMed ID: 1685600
[TBL] [Abstract][Full Text] [Related]
10. Dopamine autoreceptors modulate the in vivo release of dopamine in the frontal, cingulate and entorhinal cortices.
Altar CA; Boyar WC; Oei E; Wood PL
J Pharmacol Exp Ther; 1987 Jul; 242(1):115-20. PubMed ID: 3612520
[TBL] [Abstract][Full Text] [Related]
11. Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity.
Obuchowicz E; Krysiak R; Wieronska JM; Smialowska M; Herman ZS
Neuropeptides; 2005 Oct; 39(5):515-23. PubMed ID: 16154634
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effects of haloperidol administration on amphetamine-stimulated dopamine release in the rat medial prefrontal cortex and dorsal striatum.
Pehek EA
J Pharmacol Exp Ther; 1999 Apr; 289(1):14-23. PubMed ID: 10086982
[TBL] [Abstract][Full Text] [Related]
13. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
[TBL] [Abstract][Full Text] [Related]
14. Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain.
Kinkead B; Shahid S; Owens MJ; Nemeroff CB
J Pharmacol Exp Ther; 2000 Oct; 295(1):67-73. PubMed ID: 10991962
[TBL] [Abstract][Full Text] [Related]
15. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity?
Surmann A; Havemann-Reinecke U
J Neural Transm Suppl; 1995; 45():143-55. PubMed ID: 8748620
[TBL] [Abstract][Full Text] [Related]
16. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
[TBL] [Abstract][Full Text] [Related]
17. Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment.
Dawson NM; Hamid EH; Egan MF; Meredith GE
Synapse; 2001 Jan; 39(1):70-81. PubMed ID: 11071712
[TBL] [Abstract][Full Text] [Related]
18. Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
Perry JC; Vital MA; Frussa-Filho R; Tufik S; Palermo-Neto J
Eur Neuropsychopharmacol; 2004 Mar; 14(2):127-33. PubMed ID: 15013028
[TBL] [Abstract][Full Text] [Related]
19. Parallel development of dopamine metabolism tolerance in the rat prefrontal cortex, caudate-putamen, and amygdala following haloperidol decanoate administration.
Kurachi M; Shibata R; Murata M; Tanii Y
Biol Psychiatry; 1995 Apr; 37(7):487-90. PubMed ID: 7786966
[No Abstract] [Full Text] [Related]
20. Effects of risperidone and haloperidol on tachykinin and opioid precursor peptide mRNA levels in the caudate-putamen and nucleus accumbens of the rat.
Mijnster MJ; Schotte A; Docter GJ; Voorn P
Synapse; 1998 Apr; 28(4):302-12. PubMed ID: 9517839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
